Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GUTS Fractyl Health	$1.64 -5.7%	$1.76	$0.87 ▼ $4.92	$80.33M	1.82	364,448 shs	4.19 million shs
INO Inovio Pharmaceuticals	$2.11 -6.2%	$1.99	$1.42 ▼ $12.33	$77.37M	1.34	636,221 shs	4.78 million shs
LFWD Lifeward	$0.67 +15.2%	$1.23	$0.50 ▼ $4.77	$7.38M	0.16	786,951 shs	1.69 million shs
NTRB Nutriband	$7.98 +1.9%	$6.56	$3.72 ▼ $11.78	$88.98M	1.11	80,585 shs	58,223 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GUTS Fractyl Health	0.00%	-23.36%	-15.03%	+37.82%	-61.59%
INO Inovio Pharmaceuticals	0.00%	+7.65%	+3.94%	+29.45%	-73.89%
LFWD Lifeward	0.00%	-34.95%	-45.53%	-60.59%	-83.29%
NTRB Nutriband	0.00%	+2.44%	+28.30%	+30.18%	+47.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GUTS Fractyl Health	2.6827 of 5 stars	3.5	3.0	0.0	3.3	0.0	0.0
INO Inovio Pharmaceuticals	3.6384 of 5 stars	3.3	1.0	4.3	3.3	0.0	0.6
LFWD Lifeward	2.9165 of 5 stars	3.5	4.0	0.0	2.4	0.0	1.3
NTRB Nutriband	3.3422 of 5 stars	3.5	5.0	0.0	2.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GUTS Fractyl Health	3.00	Buy	$11.00	570.73% Upside
INO Inovio Pharmaceuticals	2.50	Moderate Buy	$9.75	362.09% Upside
LFWD Lifeward	3.00	Buy	$9.00	1,243.28% Upside
NTRB Nutriband	3.00	Buy	$13.00	62.91% Upside

Current Analyst Ratings Breakdown

Latest LFWD, INO, NTRB, and GUTS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	INO Inovio Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$5.00 ➝ $5.00
5/14/2025	INO Inovio Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $13.00
4/15/2025	GUTS Fractyl Health	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GUTS Fractyl Health	$90K	892.52	N/A	N/A	$0.59 per share	2.78
INO Inovio Pharmaceuticals	$220K	351.70	N/A	N/A	$1.90 per share	1.11
LFWD Lifeward	$25.41M	0.29	N/A	N/A	$2.14 per share	0.31
NTRB Nutriband	$2.14M	41.58	N/A	N/A	$0.58 per share	13.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GUTS Fractyl Health	-$68.69M	-$1.85	N/A	N/A	N/A	-73,864.52%	-228.66%	-76.74%	8/13/2025 (Estimated)
INO Inovio Pharmaceuticals	-$107.25M	-$3.19	N/A	N/A	N/A	N/A	-136.93%	-89.99%	8/6/2025 (Estimated)
LFWD Lifeward	-$28.94M	-$3.04	N/A	N/A	N/A	-108.21%	-101.96%	-70.49%	8/13/2025 (Estimated)
NTRB Nutriband	-$10.48M	-$0.90	N/A	N/A	N/A	-415.93%	-68.25%	-60.40%	9/2/2025 (Estimated)

Latest LFWD, INO, NTRB, and GUTS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/30/2025	Q1 2026	NTRB Nutriband	-$0.13	-$0.12	+$0.01	-$0.12	$0.71 million	$0.67 million
5/15/2025	Q1 2025	LFWD Lifeward	-$0.33	-$0.46	-$0.13	-$0.46	$5.84 million	$5.03 million
5/13/2025	Q1 2025	GUTS Fractyl Health	-$0.49	-$0.49	N/A	-$0.49	N/A	N/A
5/13/2025	Q1 2025	INO Inovio Pharmaceuticals	-$0.74	-$0.51	+$0.23	-$0.51	$0.01 million	$0.07 million
4/28/2025	Q4 2025	NTRB Nutriband	-$0.12	-$0.18	-$0.06	-$0.51	$0.71 million	$0.64 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GUTS Fractyl Health	N/A	N/A	N/A	N/A	N/A
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LFWD Lifeward	N/A	N/A	N/A	N/A	N/A
NTRB Nutriband	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GUTS Fractyl Health	4.61	2.50	2.50
INO Inovio Pharmaceuticals	N/A	2.63	2.63
LFWD Lifeward	N/A	2.18	1.43
NTRB Nutriband	0.01	3.71	3.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GUTS Fractyl Health	N/A
INO Inovio Pharmaceuticals	26.79%
LFWD Lifeward	26.76%
NTRB Nutriband	19.70%

Insider Ownership

Company	Insider Ownership
GUTS Fractyl Health	N/A
INO Inovio Pharmaceuticals	2.30%
LFWD Lifeward	2.50%
NTRB Nutriband	54.09%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GUTS Fractyl Health	102	48.98 million	N/A	N/A
INO Inovio Pharmaceuticals	320	36.67 million	35.83 million	Optionable
LFWD Lifeward	60	11.01 million	10.71 million	Optionable
NTRB Nutriband	10	11.15 million	5.12 million	Not Optionable

LFWD, INO, NTRB, and GUTS Headlines

Recent News About These Companies

Nutriband (NASDAQ:NTRB) Stock Price Up 1.7% - Here's Why

June 27 at 2:01 AM | marketbeat.com

Nutriband, Kindeva Complete Commercial Scale-up for Aversa Fentanyl

June 23, 2025 | contractpharma.comC

Nutriband (NTRB) Gets a Buy from Noble Financial

June 21, 2025 | theglobeandmail.com

Nutriband and Kindeva Complete Commercial Manufacturing Process Scale-up for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch

June 19, 2025 | manilatimes.netM

Nutriband (NASDAQ: NTRB) Secures U.S. Patent for Abuse-Deterrent Transdermal Technology

June 11, 2025 | theglobeandmail.com

Nutriband Inc.: Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology

June 9, 2025 | finanznachrichten.de

Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology

June 9, 2025 | globenewswire.com

Nutriband (NASDAQ: NTRB): A Relentless Mission Rooted in Purpose, Innovation, and Shareholder Value

June 6, 2025 | theglobeandmail.com

Research Analysts Set Expectations for Nutriband Q2 Earnings

June 5, 2025 | marketbeat.com

Nutriband (NASDAQ: NTRB) Posts Record Q1 Revenue, Advances AVERSA Fentanyl Development

June 4, 2025 | theglobeandmail.com

Nutriband Inc. to present at the 2025 Noble Capital Markets Virtual Equity Conference

June 3, 2025 | finance.yahoo.com

Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl

June 2, 2025 | finance.yahoo.com

Nutriband (NASDAQ:NTRB) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

May 31, 2025 | marketbeat.com

Nutriband Inc. (NTRB) Reports Q1 Loss, Misses Revenue Estimates

May 30, 2025 | zacks.com

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Gareth Sheridan, CEO of Nutriband Inc.

May 27, 2025 | finance.yahoo.com

Nutriband (NASDAQ: NTRB) Charts Path to Commercialization

May 24, 2025 | theglobeandmail.com

Nutriband (NASDAQ: NTRB) Pioneers Innovative Approach to Opioid Crisis with Game-Changing Transdermal Patch

May 15, 2025 | theglobeandmail.com

Nutriband projects strong sales for abuse-deterrent patches

May 1, 2025 | investing.com

Nutriband CEO Publishes Letter to Shareholders

April 30, 2025 | globenewswire.com

Nutriband granted patent in Macao for its AVERA systems

April 11, 2025 | markets.businessinsider.com

Nutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology

April 11, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFWD, INO, NTRB, and GUTS Company Descriptions

Fractyl Health NASDAQ:GUTS

$1.64 -0.10 (-5.75%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.72 +0.08 (+4.63%)

As of 09:28 AM Eastern

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Inovio Pharmaceuticals NASDAQ:INO

$2.11 -0.14 (-6.22%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.19 +0.08 (+3.60%)

As of 09:25 AM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Lifeward NASDAQ:LFWD

$0.67 +0.09 (+15.16%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.68 +0.01 (+1.49%)

As of 09:26 AM Eastern

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.

Nutriband NASDAQ:NTRB

$7.98 +0.15 (+1.92%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$8.14 +0.15 (+1.94%)

As of 09:18 AM Eastern

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time